[1] LÖWENBERG B.Acute myeloid leukemia:the challenge of capturing disease variety[J].Hematology,2008,2008(1):1-11. [2] GRIMWADE D,HILLS R K,MOORMAN A V,et al.Refinement of cytogenetic classification in acute myeloid leukemia:determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials[J].Blood,2010,116(3):354-365. [3] SHEN Y,ZHU Y M,FAN X,et al.Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia[J].Blood,2011,118(20):5593-5603. [4] O'DONNELL MR,ABBOUD CN,ALTMAN J,et al.NCCN Clinical Practice Guidelines Acute myeloid leukemia[J].J Natl Compr Canc Netw,2012,10(8):984. [5] 汤宝林,郑昌成,刘会兰,等.强化清髓性非血缘脐带血造血干细胞移植治疗急性淋巴细胞白血病的疗效观察[J].中华内科杂志,2016,55(3):191-195. [6] PRZEPIORKA D,WEISDORF D,MARTIN P,et al.1994 consensus conference on acute GVHD grading[J].Bone Marrow Transplant,1995,15(6):825-828. [7] YANO S,YOKOYAMA H,YANADA M,et al.Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission[J].Bone Marrow Transplant,2019,54(12):2004-2012. [8] DOUBEK M,MUZIK J,SZOTKOWSKI T,et al.Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)[J].Neoplasma,2007,54(1):89-94. [9] BORNHÄUSER M,ILLMER T,SCHAICH M,et al.Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML[J].Blood,2007,109(5):2264-2265. [10] BRUNET S,LABOPIN M,ESTEVE J,et al.Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission:a retrospective analysis[J].J Clin Oncol,2012,30(7):735-741. [11] HIWARKAR P,QASIM W,RICCIARDELLI I,et al.Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells[J].Blood,2015,126(26):2882-2891. [12] MILANO F,GOOLEY T,WOOD B,et al.Cord-blood transplantation in patients with minimal residual disease[J].N Engl J Med,2016,375(10):944-953. [13] PARK M,LEE S H,LEE Y H,et al.Pre-engraftme nt syndrome after unrelated cord blood transplantation:a predictor of engraftment and acute graft-versus-host disease[J].Biol Blood Marrow Transplant,2013,19(4):640-646. [14] QUINTAS-CARDAMA A,KANTARJIAN H,ANDREEF M,et al.Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)[J].J Clin Oncol,2007,25(18_suppl):7018. [15] PRATZ K W,CHO E,KARP J,et al.Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias[J].J Clin Oncol,2009,27(15_suppl):7065. [16] BORTHAKUR G,KANTARJIAN H,RAVANDI F,et al.Phase I study of sorafenib in patients with refractory or relapsed acute leukemias[J].Haematologica,2011,96(1):62-68. [17] RAVANDI F,ALATTAR M L,GRUNWALD M R,et al.Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation[J].Blood,2013,121(23):4655-4662. [18] 刘莎,魏旭东,尹青松,等.索拉非尼联合化疗治疗FLT3-ITD突变阳性急性髓系白血病九例报告并文献复习[J].中华血液学杂志,2015,36(3):241-244. [19] SHARMA M,RAVANDI F,BAYRAKTAR U D,et al.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib[J].Biol Blood Marrow Transplant,2011,17(12):1874-1877. [20] METZELDER S K,SCHROEDER T,FINCK A,et al.High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses[J].Leukemia,2012,26(11):2353-2359. [21] BRUNNERA M,LI S L,FATHI A T,et al.Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission[J].Br J Haematol,2016,175(3):496-504. [22] XUAN L,WANG Y,HUANG F,et al.Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation:an open-label,multicentre,randomised phase 3 trial[J].Lancet Oncol,2020,21(9):1201-1212. |